TTFields Plus Paclitaxel Fails to Improve Survival Among Pretreated Patients With Platinum-Resistant Ovarian Cancer
According to results from the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial, tumor treating fields (TTFields) plus paclitaxel did not improve survival compared to paclitaxel alone among pretreated patients with platinum-resistant ovarian cancer.
In this study, 558 patients who underwent ≤ 5 prior lines of therapy including ≤ 2 prior lines of therapy for platinum-resistant disease were randomized on a 1-to-1 basis to receive either 200 kHz of TTFields plus 80 mg/m2 of paclitaxel (n = 280) or paclitaxel alone (n = 278). The primary end point was overall survival (OS) in the intention-to-treat population. A key secondary end point was safety. Exploratory post-hoc analyses assessed OS in PLD-naive patients (TTFields plus paclitaxel n = 113; paclitaxel n = 88).
At analysis, median OS was 12.2 months in the TTFields plus paclitaxel arm and 11.9 months in the paclitaxel alone arm (hazard ratio [HR] 1.01; 95% confidence interval [CI], 0.83 to 1.24; P = .89). Median OS for PLD-naive patients was 16 months and 11.7 months (HR 0.67; 95% CI, 0.49 to 0.94; P = .03), respectively. The incidence of grade ≥ 3 treatment-related adverse events was similar in both arms. Grade 1/2 device-related skin adverse events occurred in 83.6% of patients.
“TTFields [plus paclitaxel] did not significantly improve OS compared with [paclitaxel] in the intent-to-treat population,” concluded Dr Vergote et al. “An exploratory post-hoc analysis suggests a potentially favorable benefit-risk profile for TTFields therapy in PLD-naive patients.”
Source:
Vergote I, Copeland LJ, Van Gorp T, et al. Tumor treating fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study. Eur J Cancer. Published online: February 17, 2025. doi: 10.1016/j.ejca.2025.115306
